Response to ciclosporin treatment in Ethiopian and Nepali patients with severe leprosy Type 1 reactions
Authors:
- S.N.S. MarloweSMS.N.S. Marlowe
- R. LeekassaRLR. Leekassa
- E. BizunehEBE. Bizuneh
- J. KnuutillaJKJ. Knuutilla
- P. AlePAP. Ale
- B. BhattaraiBBB. Bhattarai
- H. SigdelHSH. Sigdel
- A. AndersonAAA. Anderson
- P.G. NichollsPNP.G. Nicholls
- A. JohnstonAJA. Johnston
- D. HoltDHD. Holt
- D.N.J. LockwoodDLD.N.J. Lockwood
- 1 October 2007
- journal article
- Published by Oxford University Press (OUP) in Transactions of the Royal Society of Tropical Medicine and Hygiene
- Vol. 101 (10) , 1004-1012
Abstract
Leprosy type 1 reactions (T1R) are immune-mediated events with inflammation of peripheral nerves and skin. We report the clinical outcomes of a closely monitored open prospective trial in which eight Nepali and 33 Ethiopian patients with T1Rs were treated with an Indian generic formulation of ciclosporin (Cn; 5-7.5 mg/kg/day) for 12 weeks and followed up for 24 weeks after starting treatment. Outcomes were measured using a clinical severity score. Among the Nepalis, 75-100% improved in all acute clinical parameters; 67-100% patients maintained improvement, except for those with acute sensory nerve impairment among whom 67% relapsed after stopping treatment. The skin lesions of all Ethiopians on 5 mg/kg/day of Cn improved and 50-60% had peripheral nerve function improvement. Most Ethiopians needed a higher dose of Cn to improve nerve impairment and neuritis, and 50-78% of them developed worse clinical severity scores when Cn was stopped. Four Ethiopians and two Nepalis developed elevated serum creatinine levels on 7.5 mg/kg/day Cn, and three (9%) Ethiopians developed treatable hypertension. This suggests that Cn monotherapy is an effective treatment for severe T1R with few adverse effects. A dose of 5 mg/kg/day seems efficacious in Nepalis, but a higher dose may be required in Ethiopian patients.Keywords
This publication has 13 references indexed in Scilit:
- Clinical outcomes in a randomized controlled study comparing azathioprine and prednisolone versus prednisolone alone in the treatment of severe leprosy type 1 reactions in NepalTransactions of the Royal Society of Tropical Medicine and Hygiene, 2004
- Interethnic differences of drug-metabolizing enzymesInt. Journal of Clinical Pharmacology and Therapeutics, 2000
- Comparative Tolerability of Treatments for Inflammatory Bowel DiseaseDrug Safety, 2000
- Cyclosporine consensus conference: With emphasis on the treatment of psoriasisJournal of the American Academy of Dermatology, 1998
- Cyclosporin‐A therapy in severe uveitis of Behçet's diseaseActa Ophthalmologica Scandinavica, 1998
- Immunosuppressive drugs and their complicationsDrug and Therapeutics Bulletin, 1994
- Cyclosporine in Severe Ulcerative Colitis Refractory to Steroid TherapyNew England Journal of Medicine, 1994
- THE IMPACT OF ACUTE REJECTION EPISODES ON LONG-TERM GRAFT FUNCTION AND OUTCOME IN 1347 PRIMARY RENAL TRANSPLANTS TREATED BY 3 CYCLOSPORINE REGIMENSTransplantation, 1993
- A Placebo-Controlled, Double-Blind, Randomized Trial of Cyclosporine Therapy in Active Chronic Crohn's DiseaseNew England Journal of Medicine, 1989
- Low-dose cyclosporin A in severe psoriasis. A double-blind studyBritish Journal of Dermatology, 1988